ArticleBMC cancer2026
Deciphering the eRNA landscape and revealing target aberrant pathways in prostate cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnhancer RNAs (eRNAs) have emerged as important regulators of gene expression and may reshape the therapeutic landscape of prostate cancer. However, their global landscape and clinical relevance in prostate cancer remain unclear.
methodsWe systematically integrated prostate cancer multi-omics and functional genomics datasets to characterize genome-wide eRNA transcription, construct eRNA-centered regulatory networks, and link eRNA-regulated genes to clinical outcomes. Representative eRNAs and their predicted target genes were further subjected to siRNA-mediated knockdown and functional validation in prostate cancer cell lines.
resultsWe identified 13,595 eRNAs and 1,573 eRNA-regulated genes, including 266 transcription factors and 85 RNA-binding proteins. eRNA-regulated genes showed higher expression levels, lower variability, and enrichment in prostate cancer–related pathways. A five-gene eRNA-associated signature stratified patients into high- and low-risk groups with AUCs of 0.85, 0.77, and 0.89 for 1-, 3-, and 5-year survival and remained an independent prognostic factor. The two risk groups exhibited distinct genetic, transcriptomic, and epigenetic features. Functional validation further demonstrated that knockdown of representative eRNAs suppressed prostate cancer cell proliferation, migration, and invasion, accompanied by reduced expression of the target genes NUP93 and BICD1.
conclusionThese findings indicate that eRNAs may contribute to prostate cancer biology and could serve as useful markers for prognosis and pathway characterization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.